Clinical Pharmacokinetics

, Volume 17, Issue 4, pp 217–222 | Cite as

Ethical Considerations in the Conduct of Clinical Pharmacokinetic Studies

  • Craig K. Svensson
Leading Article


Antipyrine Netilmicin Ally Health Profession Phenazone Plasma Concentration Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Atiba JO, Taylor G, Pershe RA, Blaschke TF. Plasma antipyrine half-life can be determined from urine data. British Journal of Clinical Pharmacology 23: 715–719, 1987PubMedCrossRefGoogle Scholar
  2. Beauchamp TH, Childress JF. Principles of biomedical ethics, Oxford University Press, New York, 1979Google Scholar
  3. Danhof M, Breimer DD. Therapeutic drug monitoring in saliva. Clinical Pharmacokinetics 3: 39–57, 1978PubMedCrossRefGoogle Scholar
  4. Fraser HS, Mucklow JC, Murray S, Davies DS. Assessment of antipyrine kinetics by measurement in saliva. British Journal of Clinical Pharmacology 3: 321–325, 1976PubMedCrossRefGoogle Scholar
  5. James A, Koren G, Milliken J, Soldin S, Prober C. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrobial Agents and Chemotherapy 31: 52–54, 1987PubMedCrossRefGoogle Scholar
  6. Kinney EL, Trautmann J, Gold JA, Vesell ES, Zelis R. Under-representation of women in new drug trials: ramifications and remedies. Annals of Internal Medicine 95: 495–499, 1981PubMedGoogle Scholar
  7. Koren G, James A. Vancomycin dosing in preterm infants: prospective verification of new recommendations. Journal of Pediatrics 110: 797–798, 1987PubMedCrossRefGoogle Scholar
  8. Koup JR, Sack CM, Smith AL, Gibaldi M. Hypothesis for the individualisation of drug dosage. Clinical Pharmacokinetics 4: 460–469, 1979aPubMedCrossRefGoogle Scholar
  9. Koup JR, Slattery JT, Gibaldi M. Single point clearance estimation. Research Communications in Chemical Pathology and Pharmacology 25: 559–564, 1979bPubMedGoogle Scholar
  10. Levine RJ. Ethics and regulation of clinical research, 2nd ed., Urban & Schwarzenberg, Baltimore-Munich, 1986Google Scholar
  11. Long D, Koren G, James A. Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates? Journal of Pediatrics 111: 918–921, 1987PubMedCrossRefGoogle Scholar
  12. Meffin PJ, Williams RL, Blaschke TF, Rowland M. Application of salivary concentration data to pharmacokinetic studies with antipyrine. Journal of Pharmaceutical Sciences 66: 135–137, 1977PubMedCrossRefGoogle Scholar
  13. Mirkin BL. Drug therapy and the developing human: who cares? Clinical Research 23: 106–113, 1975PubMedGoogle Scholar
  14. Saeed MA, Gatens PF. Anterior interosseous nerve syndrome: unusual etiologies. Archives of Physical Medicine and Rehabilitation 64: 182, 1983PubMedGoogle Scholar
  15. Schafer A. The ethics of the randomized clinical trial. New England Journal of Medicine 307: 719–724, 1982PubMedCrossRefGoogle Scholar
  16. Svensson CK. Is blood sampling for determination of antipyrine pharmacokinetics in healthy volunteers ethically justified? Clinical Pharmacology and Therapeutics 44: 365–368, 1988PubMedCrossRefGoogle Scholar
  17. Svensson CK. Representation of American Blacks in clinical trials of new drugs. Journal of the American Medical Association 261: 263–265, 1989PubMedCrossRefGoogle Scholar
  18. Taylor G, Blaschke TF. Measurement of antipyrine half-life from urinary drug concentrations. British Journal of Clinical Pharmacology 18: 650–652, 1984PubMedCrossRefGoogle Scholar
  19. Van Boxtel CJ, Wilson JT, Lindgren S, Sjöqvist F. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. European Journal of Clinical Pharmacology 9: 327–332, 1976PubMedCrossRefGoogle Scholar
  20. Vesell ES, Passananti GT, Glenwright PA, Dvorchik BH. Studies on the disposition of antipyrine, aminopyrine, and phenacitin using plasma, saliva, and urine. Clinical Pharmacology and Therapeutics 18: 259–272, 1975PubMedGoogle Scholar
  21. Welch RM, De Angelis RL, Wingfield M, Farmer TW. Elimination of antipyrine from saliva as a measure of drug metabolism in man. Clinical Pharmacology and Therapeutics 18: 249–258, 1975PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • Craig K. Svensson
    • 1
  1. 1.Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health ProfessionsWayne State UniversityDetroitUSA

Personalised recommendations